Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing therapies that target Natural Killer T (NKT) cells for the treatment of inflammatory, fibrotic and autoimmune diseases. This news page aggregates company announcements, clinical updates and capital markets disclosures related to GRI Bio and the GRI stock.
Investors following GRI Bio’s news can track the progress of its lead program GRI-0621, an oral RARβγ agonist and iNKT activity inhibitor being developed for idiopathic pulmonary fibrosis (IPF). The company has reported interim and topline results from a Phase 2a randomized, double-blind, placebo-controlled trial in IPF, including safety and tolerability data, changes in collagen turnover biomarkers, signals of alveolar basement membrane repair and analyses of forced vital capacity (FVC). Additional releases describe immune profiling data showing iNKT inhibition and shifts toward an anti-fibrotic cytokine profile.
News items also cover interim biomarker and lung function analyses, recommendations from the Independent Data Monitoring Committee, and presentations at investor and industry conferences. These communications provide context on how GRI Bio interprets emerging clinical data and its plans for further development of GRI-0621.
Beyond clinical results, GRI Bio issues press releases on financing transactions, such as its December 2025 best efforts public offering of common stock, pre-funded warrants and Series F warrants, and related Nasdaq listing compliance updates. Governance and corporate actions, including equity incentive plan amendments and annual meeting matters, are reflected in associated SEC filings and news references.
By reviewing this GRI news feed, readers can monitor key developments in GRI Bio’s NKT cell–modulating pipeline, particularly in IPF and systemic lupus erythematosus, as well as follow capital raising activities and other material events that may be relevant to GRI stock research. Bookmark this page to access an organized stream of GRI Bio press releases and related market updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.